Bronchogen
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Bronchogen is a Khavinson tetrapeptide (Ala-Asp-Glu-Leu) targeting bronchial epithelium — part of the respiratory corner of the Khavinson short-peptide bioregulator family, alongside Chonluten. Site tier is Emerging (7 studies, 0 human).
What does it do in my body?
Claimed mechanism: like the rest of the Khavinson family, Bronchogen is proposed to modulate gene expression in a tissue-specific way — here, in bronchial epithelial cells, supporting structural and functional maintenance of the airway lining.
How can it help me?
- Where the science stands: Site tier Emerging (7 studies, 0 human) — real preclinical signal in a COPD rat model
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No serious AEs are documented for Bronchogen specifically (no human data exists to report from). The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Bronchogen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Bronchogen holds no clinical-use approval anywhere.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for Bronchogen are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.
There is no Western-validated dosing protocol for Bronchogen — the evidence base is animal-only. What exists is the Khavinson-school cycle pattern shared across the family:
- Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year.
- Dose: as a synthetic short tetrapeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the cycle; no Bronchogen-specific human dose-finding data exists.
- Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.
Treat every number above as community/Russian-protocol convergence, not validated dosing.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.
What should I avoid combining — and what's synergistic?
Bronchogen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
Bronchogen is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Bronchogen (Ala-Asp-Glu-Leu / AEDL) is a Khavinson tetrapeptide for bronchial epithelium — and it carries the most concrete organ-regeneration signal in the whole provisional (D-grade) corner of the Khavinson family, on the strength of a real COPD rat model. Still animal-only; no human work exists.
| Class | Khavinson tetrapeptide — Ala-Asp-Glu-Leu (AEDL) |
| Mechanism (one line) | Claimed to modulate gene expression in bronchial epithelium, supporting respiratory tissue structure and function |
| Evidence base | Site tier Emerging (7 studies, 0 human) — real preclinical signal in a COPD rat model |
| Safety record | No serious AEs documented; family-wide mild profile; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Bronchogen is a Khavinson tetrapeptide (Ala-Asp-Glu-Leu) targeting bronchial epithelium — part of the respiratory corner of the Khavinson short-peptide bioregulator family, alongside Chonluten. Site tier is Emerging (7 studies, 0 human).
How it works
Claimed mechanism: like the rest of the Khavinson family, Bronchogen is proposed to modulate gene expression in a tissue-specific way — here, in bronchial epithelial cells, supporting structural and functional maintenance of the airway lining.
What the research shows
Real preclinical signal in a COPD model (all pending citation-verification pass):
- Reduced lung inflammation and restored bronchial-epithelium structure in a COPD rat model (Titova et al. 2017, 30199201; Kuzubova et al. 2015, Bull Exp Biol Med, 26468022).
- Increased DNA thermostability / DNA-stabilizing properties for the AEDL sequence (Monaselidze et al. 2011, 21240358) — this is the citation that pins the sequence.
The COPD-model data is the most concrete organ-regeneration signal in the provisional set of the Khavinson family. Still animal-only; no human work. OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.
There is no Western-validated dosing protocol for Bronchogen — the evidence base is animal-only. What exists is the Khavinson-school cycle pattern shared across the family:
- Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year.
- Dose: as a synthetic short tetrapeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the cycle; no Bronchogen-specific human dose-finding data exists.
- Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.
Treat every number above as community/Russian-protocol convergence, not validated dosing.
Side effects & management
No serious AEs are documented for Bronchogen specifically (no human data exists to report from). The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Bronchogen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Bronchogen holds no clinical-use approval anywhere.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Bronchogen kept D-provisional / encyclopedia-only.
- PMIDs: 30199201 (Titova et al. 2017), 26468022 (Kuzubova et al. 2015); 21240358 (Monaselidze et al. 2011, sequence-pinning citation).
- Related: Chonluten · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Bronchogen kept D-provisional / encyclopedia-only.
- PMIDs: 30199201 (Titova et al. 2017), 26468022 (Kuzubova et al. 2015); 21240358 (Monaselidze et al. 2011, sequence-pinning citation).
- Related: Chonluten · the Khavinson bioregulator family.